PHS39 Cost-effectiveness analysis of home haemodialysis for diabetes mellitus population in Taiwan  by Hsu, J.C.
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A191 
 
 
required to recoup the intervention cost sooner. In this study, we focused on 
persons at high risks for both hypertension and diabetes and assessed the cost-
effectiveness of lifestyle interventions from a health plan perspective. 
METHODS: We used a Markov-based discrete event model to simulate the health 
and economic outcomes associated with lifestyle interventions compared with 
normal care over persons’ lifetime. The target population is U.S. adults with both 
prehypertension (a systolic blood pressure of 120-139 mm Hg or diastolic blood 
pressure of 80-89 mm Hg) and prediabetes. Data on the effect and costs of the 
intervention were obtained from published clinical trials. Outcomes included the 
incidences of diabetes and cardiovascular diseases, quality adjusted life years 
(QALY), and cost per QALY. Costs were expressed in 2012 US dollar. RESULTS: In 
persons aged 18-64, the intervention reduced the incidence of diabetes by 22% 
and major cardiovascular diseases by 7% over a lifetime. In persons aged 65-84, 
the corresponding reductions were 32% and 3% respectively. The intervention 
would save $3,500 and $1,500 per person among those aged 18-64 and 65-84 
respectively. The intervention achieved cost-even in 10 years among those aged 
18-64 and in 6 years among those aged 65-84 since initiation. CONCLUSIONS: 
Lifestyle intervention, targeting to persons at a high risk for both hypertension 
and diabetes, would lead to a greater lifetime saving and sooner recovery of the 
intervention costs, compared with targeting to those at risk for diabetes alone.  
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OBJECTIVES: Many children undergoing renal transplantation are vitamin D 
deficient, and hence, have an elevated risk of fracture, a costly event that can 
also reduce quality of life substantially. However, because testing a child’s 
vitamin D concentration is also costly, it makes sense to investigate whether 
universal vitamin D supplementation is more cost-effective than testing 
followed by supplementation for deficient patients only. The objective of this 
study was to determine the cost-effectiveness of (1) universal supplementation 
relative to (2) testing plus supplementation in patients with vitamin D deficiency 
and (3) neither testing nor supplementation. METHODS: A non-Markov decision 
model using Decision Maker (beta test version 2011.01.30b) was constructed to 
examine the three strategies: universal supplementation; testing with 
supplementation as needed; and no testing/supplementation. A time horizon of 
five years was assumed, and analysis was done from the health-system’s 
perspective. Probabilities, costs, and utilities were obtained from published 
literature and health-system. A 3% discount rate was applied to costs and results 
were reported in 2011 $US. Sensitivity and threshold analyses were conducted. 
RESULTS: The least costly strategy was universal supplementation which 
dominated no testing/ supplementation. The ICER for testing was 
$1,188,622/QALY compared with universal supplementation. The only parameter 
in the model that demonstrated sensitivity was the cost of testing. If it were 
reduced to $39.30 (from present cost of $102.11); then testing would become the 
dominant strategy. CONCLUSIONS: This study showed that universal vitamin D 
supplementation was a cost-effective strategy for reducing fractures among the 
pediatric renal transplant population. This strategy is further supported by the 
observation that supratherapeutic doses of vitamin D are rarely associated with 
toxicity and only at very extreme doses, although watching for toxicity would 
require adequate monitoring. The pleiotropic effects, i.e., decreased rejection of 
vitamin D supplementation may lower the cost per QALY and needs to be 
explored.  
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OBJECTIVES: To evaluate the cost effectiveness of ‘sore throat clinics’ (STCs) for 
prevention of acute rheumatic fever (ARF) in children in primary/intermediate 
schools. METHODS: A Markov model was developed to represent the lifetime 
impact of one year of primary prevention of ARF with STCs in high risk New 
Zealand (NZ) schools. It includes the incidence rate, natural history and costs of 
ARF and rheumatic heart disease; secondary prophylaxis; medical management 
of carditis; cardiac valve repair/replacement; the overall efficacy of community 
interventions to prevent rheumatic fever; and the annual cost per child of STCs. 
The model has a cycle of one year and terminates at age 95. It takes a health care 
payer perspective but excludes costs to families. Future costs and health benefits 
are discounted at 3.5% per annum. RESULTS: If STCs are 59% efficacious and cost 
on average NZ$135 per child per year, for schools at an incidence rate of 75 per 
100,000, STCs can be expected to cost about NZ$60,000 per QALY gained or 
NZ$190,000 per ARF case averted or NZ$2m per death averted. These figures are 
sensitive to the efficacy and annual cost of the intervention and the incidence of 
ARF but robust to uncertainty in other variables. The main costs are for project 
workers and laboratory culture and the main uncertainty is the efficacy of the 
intervention in NZ high risk schools. CONCLUSIONS: Sore throat clinics in high 
risk schools are likely to reduce the risk of acute rheumatic fever and thereby 
improve survival of Mâori and Pacific children, although they appear to be poorly 
cost effective from a NZ government perspective. Their cost effectiveness could 
be improved by containing staffing costs and/or reducing the cost of laboratory 
diagnosis of GAS. Implementation of this intervention would reduce the striking 
disparity between Mâori/Pacific and others.  
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OBJECTIVES: Delirium is common in hospitalised older patients and leads to 
poor long term outcomes. An ageing population means it is important to find 
cost-effective methods for both treatment and prevention. However, few 
economic evaluations of delirium interventions exist. This study generated an 
economic model to estimate the cost-effectiveness of an integrated, multi-
component targeted intervention (MTI) versus usual care for the prevention of 
delirium in elderly hospitalised patients. METHODS: A cohort Markov model 
was developed to calculate expected lifetime costs (health and social services 
perspective) and benefits (QALYs). Model face validity was checked with 
clinical experts and internal validity via secondary researchers. Health states 
were: dead, hospitalised, discharge location (home vs. institution). Utility 
values (SF-6D) were taken from a previous quality of life study. There was 
longer hospital stay, higher mortality rates and institutionalisation and lower 
utility values post delirium. Deterministic and probabilistic sensitivity 
analyses assessed uncertainty surrounding the incremental cost-effectiveness 
ratio (ICER). Value of information analysis was also conducted. RESULTS: With 
the MTI reducing delirium probability by one third, the deterministic ICER was 
just over £1000 per incremental QALY versus usual care. Probabilistic 
sensitivity analysis suggests there is 100% probability of cost-effectiveness 
when the QALY threshold is £30,000. At this threshold there is no expected 
value of perfect information (EVPI). Results were robust to one-way sensitivity 
analyses including changes in MTI effectiveness, delirium incidence and 
length of stay. CONCLUSIONS: The new decision model is a valid and useful 
tool for evaluating delirium interventions. In this analysis it indicates the MTI 
is highly cost-effective compared to usual care. Future research should focus 
on determining the impact of delirium on relative length of stay and on 
clarifying the utility values of elderly hospitalised patients with and without 
delirium.  
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OBJECTIVES: The number of patients with end-stage renal disease (ERSD) has 
rapidly increased globally. The incidence rate and prevalent rate on ERSD in 
Taiwan are in the first place of the world. While home haemodialysis (HHD) has 
been commonly used for ERSD patients in many countries, it has not been 
available in Taiwan. This study aims to assess the feasibility of HHD by 
conducting the cost-effectiveness analysis of different regimes of haemodialysis 
(hospital-based, satellite-based and home-based) from the perspectives of both 
patient and government. METHODS: A cost-effectiveness analysis was 
conducted based on a state transition Markov model for new ERSD patients with 
diabetes mellitus (DM) in Taiwan. Using published data from existing empirical 
studies, the incremental cost-effectiveness ratios (ICER) were calculated, and the 
cost-effectiveness acceptability curves (CEAC) were used to illustrate the results. 
Sensitivity analyses were implemented based on different costs of haemodialysis 
machines and transition rates. RESULTS: Satellite-based haemodialysis is the 
most economical choice in the initial stages of treatment. However, home 
haemodialysis becomes the most cost-effective after the twenty-third month 
(ICER=-US$126/utility), and becomes the most inexpensive choice after the third 
year. Compared with hospital-based and satellite-based haemodialysis, home 
haemodialysis saves about US$20,000 and US$13,500 in the end of the third year 
respectively, and US$55,000 and US$45,000 in the end of the fifth year 
respectively. Totally US$110 million was estimated to be saved in the end of 
third year once 10% of patients transfer from hospital-based haemodialysis to 
home haemodialysis in Taiwan. CONCLUSIONS: Given the better cost-
effectiveness of home haemodialysis, and its several advantages like more stable 
blood pressure, the elastic treatment time, privacy, and suitable for daily 
workers and disable patients compared with other haemodialyses, home 
haemodialysis is suggested to be the newly alternative choice for DM patients in 
Taiwan.  
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OBJECTIVES: To assess cost-utility of the prophylactic HPV vaccination on the 
prevention of ICC in brazilian amazonic region (State of Roraima). Invasive 
cervical cancer (ICC) remains an important public health problem, particularly in 
developing countries. The brazilian amazonic region is an high incidence area of 
ICC, comparable to low-income countries (crude incidence rate: 46/100.000), what 
suggests weaknesses in the current secondary prevention program. METHODS: 
A Markov model was developed as an analytic tool to simulate the natural 
history of HPV and its progress to ICC, considering the current preventive 
programs. Transition probabilities assumptions were based mainly on empirical 
data of local and national studies. The model evaluated the addition of the 
vaccine to 3 cervical cancer screening scenarios (0, 3 or 10 exams throughout 
life). RESULTS: The scenario of three Pap tests resulted in satisfactory calibration 
(base case). The addition of HPV vaccination would reduce by 35% the incidence 
